National Oncology Alliance (NOA) wants more subsidies for rare cancers

PBS landscape
Oncologists say thousands of cancer patients are either missing out on medication or being forced to spend large portions of their savings on potentially life-saving treatments because of gaps in the PBS.

The National Oncology Alliance (NOA) is calling on the Pharmaceutical Benefits Advisory Committee (PBAC) to subsidise more rare cancer treatments.

Read ABC News story here

 

Share this article

Subscribe to our Newsletter

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Related News

NECA Joins Boehringer Ingelheim Panel Discussion on Clinical Trials and Patient Access

Expressions of interest open for ANZSNM nurse and allied health workshop in Canberra

NECA partners with Oncidium ahead of World Radiotheranostics Day 2026

Bringing Together Experts to Improve NET Patient Care: NECA at the 5th NET Preceptorship

Tax Appeal

Screenshot 2026-05-20 at 2.12.07 PM

Help 31,000+ neuroendocrine cancer patients get the specialised care they deserve.

Every dollar raised is fully tax deductible and helps fund much needed advocacy efforts and patient support.